"Further to the request on 31 May 2022 for the securities of ResApp Health Limited (“Company”) to be placed in trading halt, the Company hereby requests that its securities be placed in voluntary suspension in accordance with ASX Listing Rule 17.2, pending the release of an announcement by the Company providing an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in the Company by way of a Scheme of Arrangement.
The Company requests that the voluntary suspension ends on the date the anticipated announcement referred to above is released to the market which the Company anticipates will occur by Monday 6 June 2022".
RAP Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
